Lars Holger Ehlers
Overview
Explore the profile of Lars Holger Ehlers including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
42
Citations
408
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ehlers L, Reinstrup N, Olesen R, Holm J, McEwan P, le Roux C
Int J Obes (Lond)
. 2024 Oct;
49(2):246-253.
PMID: 39414950
The treatment of obesity remains underprioritized. New pharmacologic options for the treatment of obesity have shown effectiveness and safety but are not widely reimbursed. Despite the unmet need and the...
2.
Slot M, Rasmussen T, Norgaard M, Larsen C, Ehlers L
Pharmacoecon Open
. 2024 Jul;
8(6):847-856.
PMID: 39080141
Objective: To estimate the costs and cost-effectiveness of introducing highly active antiretroviral therapy (HAART) in Denmark based on real-world evidence for the three treatment eras pre-HAART (1985-1995), early HAART (1996-2005),...
3.
Jorgensen E, Muttuvelu D, Peto T, Natarajan S, Davies J, Keane P, et al.
Eye (Lond)
. 2024 Jun;
38(14):2788-2795.
PMID: 38834842
Background And Purpose: Optometrist-assisted and teleophthalmology-enabled referral pathway (OTRP) for community optometry referrals has the potential to improve the capacity and efficiency of eye care delivery systems through risk stratification...
4.
Theilgaard-Monch K, Ehlers L
Nat Rev Clin Oncol
. 2023 Oct;
21(2):81-82.
PMID: 37845305
No abstract available.
5.
Vestergaard A, Ehlers L, Neergaard M, Christiansen C, Valentin J, Johnsen S
Pharmacoecon Open
. 2023 Aug;
7(5):751-764.
PMID: 37552432
Objectives: To examine costs of care from a healthcare sector perspective within 1 year before death in patients with non-cancer diseases and patients with cancer. Methods: This nationwide registry-based study...
6.
Riel H, Vicenzino B, Olesen J, Jensen M, Ehlers L, Rathleff M
Br J Sports Med
. 2023 Jul;
57(18):1180-1186.
PMID: 37414460
Objective: To compare the effectiveness of patient advice plus heel cup alone (PA) versus PA and lower limb exercise (PAX) versus PAX plus corticosteroid injection (PAXI) to improve self-reported pain...
7.
Laursen H, Jorgensen E, Vestergaard P, Ehlers L
Pharmacoeconomics
. 2023 Jul;
41(11):1469-1514.
PMID: 37410277
Background: We performed a systematic overview of the cost-effectiveness analyses (CEAs) comparing Non-insulin antidiabetic drugs (NIADs) with other NIADs for the treatment of type 2 diabetes mellitus (T2DM), using decision-analytical...
8.
Slot M, Niemann C, Ehlers L, Rotbain E
Blood Adv
. 2023 May;
7(15):4186-4196.
PMID: 37184985
Several targeted treatments, such as venetoclax + obinutuzumab (VenO) and ibrutinib, have been developed to treat patients with treatment-naive chronic lymphocytic leukemia (CLL) and have been shown to improve progression-free...
9.
Jacob J, Biering-Sorensen T, Ehlers L, Edwards C, Mohn K, Nilsson A, et al.
Vaccines (Basel)
. 2023 Apr;
11(4).
PMID: 37112667
Individuals aged 65 years and above are at increased risk of complications and death from influenza compared with any other age group. Enhanced vaccines, as the MF59-adjuvanted quadrivalent influenza vaccine...
10.
Ehlers L, Axelsen F, Rasmussen T, Dollerup J, Jespersen N, Larsen C, et al.
HIV Med
. 2022 Oct;
24(4):453-461.
PMID: 36274224
Objective: To estimate the economic burden of non-communicable diseases (NCDs) in people living with HIV (PLWH) in Denmark. Methods: We conducted a cohort study using population-based Danish medical registries including...